Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00504829 · ClinicalTrials.gov registry record · Phase 2

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

A Phase 2 study of Dyslipidemia, sponsored by Veloxis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
220
Enrollment target
1
Study location

NCT00504829 is a Phase 2 study of Dyslipidemia that has completed, run by Veloxis Pharmaceuticals. The registered enrollment target is 220 participants, below the 358-participant average among 40 other Dyslipidemia trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00504829, a Phase 2 study of Dyslipidemia, has completed, sponsored by Veloxis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
220 participants
Enrollment target
1
Study location

Study Summary

The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.

Conditions Studied

Dyslipidemia

Interventions

  • DRUG atorvastatin
  • DRUG fenofibrate
  • DRUG LCP-AtorFen

Study Locations (1)

Illinois

  • Radiant Research, 515 N State Street, Suite 2700 - Chicago

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2007-07
Est. Completion 2008-07
Phase Phase 2

Sponsor

Veloxis Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00504829

The ClinicalTrials.gov registry entry for NCT00504829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 40 other Dyslipidemia trials with a reported enrollment target (39% lower). The listed sponsor is Veloxis Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 3 interventions - of which atorvastatin is the first listed.

NCT00504829 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00504829 about?

NCT00504829 is a clinical study titled "Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia". The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.

What is the current status of trial NCT00504829?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2007-07. Estimated completion is 2008-07.

What conditions does trial NCT00504829 study?

This clinical trial studies the following conditions: Dyslipidemia.

What interventions are being tested in trial NCT00504829?

The interventions under investigation include: atorvastatin (DRUG), fenofibrate (DRUG), LCP-AtorFen (DRUG).

Who is sponsoring clinical trial NCT00504829?

This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00504829 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dyslipidemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dyslipidemia

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.